Literature DB >> 30303340

Challenges and future developments in liver transplantation.

Pierluigi Toniutto1, Davide Bitetto2, Ezio Fornasiere2, Elisa Fumolo2.   

Abstract

Liver transplantation (LT) has become the treatment of choice for a wide range of liver diseases in both adult and pediatric patients. Until recently, the largest proportion of LT in adults, were performed in patients with hepatitis C (HCV) related cirrhosis. The recent availability of safe and effective direct antiviral agents to cure HCV infection in almost all patients whatever the HCV genotype and severity of liver disease, will reduce the need for LT in this category of recipients. Thus, it is presumed that in the next 1 to 2 decades HCV related liver disease will diminish substantially, whereas non-alcoholic steato-hepatitis (NASH) will correspondingly escalate as an indication for LT. The greatest challenges facing LT remain the limited supply of donor organs, and the need for chronic immunosuppression, which represent the true obstacles to the greater application and durable success of the LT procedure. This review aimed to highlight, in different sections, the main open issues and future developments in LT. These will be focused to explore current and future strategies to maximize the use of limited organs, to offer an update on potential new approaches to immunosuppression and to imagine new indications for LT when the number of patients awaiting transplants for HCV related liver disease is reduced.

Entities:  

Mesh:

Year:  2018        PMID: 30303340     DOI: 10.23736/S1121-421X.18.02529-1

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  5 in total

1.  Therapeutic effects of mesenchymal stem cells-conditioned medium derived from suspension cultivation or silymarin on liver failure mice.

Authors:  Sedigheh Molaei; Fatemeh Amiri; Rasoul Salimi; Shirin Ferdowsi; Marzie Bahadori
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

Review 2.  Transplanting Marginal Organs in the Era of Modern Machine Perfusion and Advanced Organ Monitoring.

Authors:  Thomas Resch; Benno Cardini; Rupert Oberhuber; Annemarie Weissenbacher; Julia Dumfarth; Christoph Krapf; Claudia Boesmueller; Dietmar Oefner; Michael Grimm; Sefan Schneeberger
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

Review 3.  The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future.

Authors:  Yusuke Watanabe; Atsunori Tsuchiya; Shuji Terai
Journal:  Clin Mol Hepatol       Date:  2020-12-03

4.  Circulating Extracellular Vesicles Contain Liver-Derived RNA Species as Indicators of Severe Cholestasis-Induced Early Liver Fibrosis in Mice.

Authors:  Sharmila Fagoonee; Maddalena Arigoni; Marta Manco; Martina Olivero; Francesca Bizzaro; Cinzia Magagnotti; Annapaola Andolfo; Barbara Miniscalco; Marco Forni; Stefano Todeschi; Emanuela Tolosano; Elena Bocchietto; Raffaele Calogero; Fiorella Altruda
Journal:  Antioxid Redox Signal       Date:  2022-01-04       Impact factor: 8.401

Review 5.  Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases.

Authors:  Viviana Cernigliaro; Rossella Peluso; Beatrice Zedda; Lorenzo Silengo; Emanuela Tolosano; Rinaldo Pellicano; Fiorella Altruda; Sharmila Fagoonee
Journal:  Cells       Date:  2020-02-07       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.